Walleye Capital’s Anavex Life Sciences AVXL Stock Holding History

Walleye Capital’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55K	Sell	600 -24,700	-98%	-$73.1K	﹤0.01%	4596
2026 Q1	$77.7K	Buy	25,300 +5,300	+27%	+$23K	﹤0.01%	3761
2025 Q4	$71.2K	Buy	+20,000	New	+$123K	﹤0.01%	3986
2025 Q2	–	Sell	-23,600	Closed	-$202K	–	4496
2025 Q1	$202K	Buy	23,600 +13,500	+134%	+$127K	﹤0.01%	3255
2024 Q4	$108K	Buy	+10,100	New	+$77.7K	﹤0.01%	4102
2024 Q3	–	Sell	-23,400	Closed	-$98.7K	–	5276
2024 Q2	$98.7K	Sell	23,400 -2,700	-10%	-$10.9K	﹤0.01%	4723
2024 Q1	$133K	Buy	26,100 +4,800	+23%	+$27K	﹤0.01%	4224
2023 Q4	$198K	Buy	+21,300	New	+$147K	﹤0.01%	3682
2023 Q3	–	Sell	-1,500	Closed	-$12.2K	–	4853
2023 Q2	$12.2K	Sell	1,500 -1,000	-40%	-$8.57K	﹤0.01%	3882
2023 Q1	$21.4K	Buy	+2,500	New	+$25K	﹤0.01%	3393

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Walleye Capital's AVXL Position: Q2 2026 in Review

Walleye Capital reduced its Anavex Life Sciences (AVXL) stake by 24% in Q2 2026, selling an estimated $284 and leaving 302 shares worth $782. The position accounts for ﹤0.01% of the portfolio, ranked #4612.

Walleye Capital first reported a position in AVXL in Q4 2025 and has held it in 3 quarters since. The position peaked at $21.4K in Q4 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

Walleye Capital held 302 shares of Anavex Life Sciences worth $782 as of Q2 2026.
Walleye Capital sold 96 Anavex Life Sciences shares in Q2 2026, an estimated $284.
Anavex Life Sciences made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4612 holding.
Walleye Capital first reported a position in Anavex Life Sciences in Q4 2025 and has held it in 3 quarters since.
Walleye Capital's Anavex Life Sciences position peaked at $21.4K in Q4 2025.
179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.